Condition: Gastric Cancer With Peritoneal Dissemination · Sponsor: Research Institute for Physical Chemical Problems of the Belarusian State University
It is planned to conduct an open-label, prospective, randomized clinical study of the efficacy, tolerability and safety of a single intraperitoneal administration of the investigational drug Prospidelong at a dose of 4000 mg (2000 mg in terms of prospidium chloride) in patients with disseminated gastric cancer. In total, the study plans to include 120 patients aged 18 to 75 years inclusive, including 60 patients in the study group and 60 in the comparison group. The study consists of daily examination of patients throughout the entire period of hospitalization and subsequent visits.
This description comes directly from the study's public registry record.
Eugen Grinyuk, Ph.D., Associate professor · +375 17 209-52-54 · hryniuk@bsu.by
Pavel Bychkovsky, Ph.D., Associate Professor · +375 17 209-58-40 · bychkovsky@tut.by
Always discuss trial participation with your own doctor first.
| The state institution N. N. Alexandrov National Cancer Centre of Belarus | Minsk, Minsk City, Belarus | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06232434